The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes : The ACS EuroPath IV project
Laufs, Ulrich (Universitätsklinikum Leipzig)
Catapano, Alberico Luigi (IRCCS MultiMedica (Milà, Itàlia))
De Caterina, Raffaele (Pisa University Hospital)
Schiele, François (University of Burgundy Franche-Comte)
Sionis, Alessandro (Institut d'Investigació Biomèdica Sant Pau)
Zaman, Azfar (Freeman Hospital and Newcastle University)
Jukema, J. Wouter (The Netherlands Heart Institute)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	To evaluate the effect of the ESC/EAS 2019 dyslipidaemia guidelines on patient management of lipid-lowering therapy in patients with acute coronary syndrome (ACS), through a survey designed to compare post-ACS patient management in 2022 with that in 2018. Online questionnaires focused on lipid profile and medications were used to gather data from 2650 ACS patients in 6 European countries, treated between March-June 2022 (ACS EuroPath IV survey). These data were compared with data collected from 2650 patients who participated in the ACS EuroPath I survey (conducted in 2018). Lipid testing was performed in 90% of patients and was done sooner after admission in 2022 versus 2018 (mean 1. 4 vs 1. 7 days). Increased testing for non-HDL-C, lipoprotein(a), and ApoB was observed over time. At discharge, most patients (≥90%) were receiving lipid-lowering therapy. Prescribing patterns differed, with a higher proportion of patients receiving statin plus ezetimibe combination therapy in 2022 versus 2018 (34% vs 13%). LDL-C levels were lower in 2022 versus 2018 at admission and at 1st, 2nd and 3rd post-discharge follow-up points. More patients achieved low-density lipoprotein cholesterol (LDL-C) goals in 2022 versus 2018 at the first follow-up (average 14 vs 16 weeks since discharge; <70 mg/dL [1. 8 mmol/L]: 34% vs 20%; <55 mg/dL [1. 4 mmol/L]: 18% vs 10%) and at subsequent follow-up points. LDL-C goal achievement has improved since the release of the 2019 guidelines, but lipid management in post-ACS patients remains suboptimal.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Acute coronary syndrome ; Dyslipidaemia ; Guidelines ; Lipids
Publicat a:	Vascular Pharmacology, Vol. 148 (february 2023) , p. 107141, ISSN 1879-3649

DOI: 10.1016/j.vph.2023.107141
PMID: 36626974

8 p, 425.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats